Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease

Annals of Pharmacotherapy

Volumn 33, Issue 4, 1999, Pages 441-450

  Krall, Wanda J ^a   Sramek, John J ^a   Cutler, Neal R ^b  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b NONE

Author keywords

Acetylcholinesterase; Alzheimer disease; Inhibitors

Indexed keywords

AMINOACRIDINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METRIFONATE; PHYSOSTIGMINE; PIPERIDINE; RIVASTIGMINE; TACRINE;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; CHOLINERGIC TRANSMISSION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS;

EID: 0032931885     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18211     Document Type: Review

References (129)

1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde, Zentralbl Neurol Psychiatr 1907;18:177-9.
2. Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM, eds. Alzheimer's disease: biology, diagnosis and therapeutics. Chichester, England: Wiley, 1997.
3. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-14.
4. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-90.
5. Davies P, Maloney AF. Selective loss of central cholinergic neurons in Alzheimer's disease (letter). Lancet 1976;2:1403.
6. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic and decarboxylase activities in necropsy brain tissue. J Neurosci 1977;34:247-65.
7. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457-9.
8. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence of selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-6.
9. Cutler NR, Sramek JJ. The potential of muscarinic M1 agonists in the treatment of Alzheimer's disease. CNS Drugs 1995;3:467-81.
10. Giacobini E. New trends in cholinergic therapy for Alzheimer's disease: nicotinic agonists or cholinesterase inhibitors? Prog Brain Res 1996;109: 311-23.
11. Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease. The way forward. Drugs 1997;53:752-68.
12. Arendt T, Bigl V, Tennstedt A, Arendt A. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease. Neuroscience 1985;14:1-14.
13. Etienne P, Robitaille Y, Wood P, Gauthier S, Nair NP, Quirion R. Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Neuroscience 1986;19:1279-91.
14. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992;258:304-7.
15. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc Natl Acad Sci U S A 1992;89:10075-8.
16. Giacobini E, Mori F, Lai CC. The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex. Ann N Y Acad Sci 1996; 777:393-8.
17. Roberson MR, Harrell LE. Cholinergic activity and amyloid precursor protein metabolism. Brain Res Brain Res Rev 1997;25:50-69.
18. Cutler NR, Sramek JJ, Veroff AE. Alzheimer's disease: optimizing drug development strategies. Chichester, England: Wiley, 1994.
19. Bon S, Vigny M, Massoulie J. Asymmetric and globular forms of acetylcholinesterase in mammals and birds. Proc Natl Acad Sci U S A 1979; 76:2546-50.
20. Siek GC, Katz LS, Fishman EB, Korosi TS, Marquis JK. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain. Biol Psychiatry 1990;27:573-80.
21. Rosenberry TL, Scoggin DM. Structure of human erythrocyte acetylcholinesterase. J Biol Chem 1984;259:5643-52.
22. St Clair DM, Brock DJH, Barron L. A monoclonal antibody assay technique for plasma and red cell acetylcholinesterase activity in Alzheimer's disease. J Neurol Sci 1986;73:169-76.
23. Taylor P. Anticholinesterase agents. In: Hardiman JG, Limbird LE, Molinoff PB, Ruddon RW, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:161.
24. Holmes JH, Gaeon MD. Observations on acute and multiple exposure to anticholinesterase agents. Trans Am Clin Climatol Assoc 1957;68:86-101.
25. Bartus RT. Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 1978;9:833-6.
26. Mohs RC, Davis BM, Johns CA, Mathe AA, Greenwald BS, Horvath TB, et al. Oral physostigmine in treatment of patients with Alzheimer's disease. Am J Psychiatry 1985;142:28-33.
27. Summers W, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-5.
28. Wagstaff AJ, McTavish D. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in Alzheimer's disease. Drugs Aging 1994;4:510-40.
29. Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996;47:1389-95.
30. Murphy MF, Hardiman ST, Nash RJ, Huff J, Demokovich JJ, Dobson C, et al. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease. Ann N Y Acad Sci 1991;640:253-62.
31. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-9.
32. Physicians' desk reference. 53rd ed. Montvale, NJ: Medical Economics Co., 1999:2364.
33. Poirier J, Delisle M-C, Quirion R, Aubert I, Farlow M, Lahiri D, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995;92: 12260-4.
34. Cutler NR, Sramek JJ, Kurtz NM, Murphy MF, Carta A. Accelerating CNS drug development. Chichester, England: Wiley, 1998.
35. Cutler NR, Sramek JJ. The role of bridging studies in the development of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 1998;10: 355-64.
36. Cutler NR, Sramek JJ. Guidelines for conducting bridging studies in Alzheimer's disease. Alzheimer Dis Assoc Disord 1998;12:88-92.
37. Cutler NR, Sramek JJ. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol 1995;48: 421-8.
38. Cutler NR, Sramek JJ. Considerations for clinical trials in Alzheimer's disease. In: Brioni JD, Decker MW, eds. Pharmacological treatment of Alzheimer's disease: molecular and neurobiological foundations. New York: Wiley, 1997:367-87.
39. Cutler NR, Sramek JJ, Kilborn JR. The bridging concept: optimizing dose for Phase II/III in Alzheimer's disease. Neurodegeneration 1996;5: 511-4.
40. Cutler NR, Sramek JJ, Greenblatt DJ, Chaikin P, Ford N, Lesko LJ, et al. Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectives. J Clin Pharmacol 1997;37:767-83.
41. Thomsen T, Kewitz H, Pleul O. Estimation of cholinesterase activity (EC 3.1.1.7;3.1.1.8) in undiluted plasma and erythrocytes as a tool for measuring in vivo effects of reversible inhibitors. J Clin Chem Clin Biochem 1988;26:469-75.
42. Canal N, Imbimbo BP. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Clin Pharm Ther 1996;60:218-28.
43. Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S, et al. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer's disease. Alzheimer Dis Assoc Disord 1996;10:124-31.
44. Cummings J, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate in Alzheimer's disease: results of a dose-finding study. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM, eds. Alzheimer's disease: biology, diagnosis and therapeutics. Chichester, England: Wiley, 1997:665-9.
45. Pettigrew LC, Bieber F, Lettieri J, Wermeling DP, Schmitt FA, Tikhtman AJ, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998;38: 236-45.
46. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50:1214-21.
47. Johansson M, Hellstrom-Lindahl E, Nordberg A. Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. Dementia 1996;7:111-7.
48. Friedhoff LT, Rogers SL. Correlation between the clinical efficacy of donepezil HCl and red blood cell acetylcholinesterase (AChE) inhibition in patients with Alzheimer's disease (AD) (abstract). Clin Pharm Ther 1997;61:177.
49. Rainer M, Mucke H, Janoch P, Reiss A, Haushofer M, Kewitz H. Galanthamine treatment in Alzheimer's disease - the identification of responders (abstract). Neuropsychopharmacology 1994;10(suppl):215S.
50. Cutler NR, Polinsky RJ, Sramek JJ, Enz A, Jhee SS, Mancione L, et al. Dose-dependent inhibition of CSF acetylcholinesterase by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998;97:244-50.
51. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
52. Kramer-Ginsberg E, Mohs RC, Aryan M, Lobel D, Silverman J, Davidson M, et al. Clinical predictors of course of Alzheimer's patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988;24: 458-62.
53. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al. A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive degeneration. Am J Psychiatry 1994;151:390-6.
54. Peripheral and Central Nervous System Drugs Advisory Committee Meeting, July 7, 1989. Rockville, MD: Department of Health and Human Services, Public Health Service, Food and Drug Administration, 1989:227.
55. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-21.
56. Veroff AE, Cutler NR, Prior PL, Mickelson W, Hartman JK, Sramek JJ. A new assessment tool for neuropsychopharmacologic research: the Computerized Neuropsychological Test Battery. J Geriatr Psychiatry Neurol 1991;4:211-7.
57. Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. The efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery. Alzheimer Dis Assoc Disord 1998;12:304-12.
58. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33-9.
59. Folstein MF, Folstein S, McHugh P. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
60. Thomsen T, Kaden B, Fischer JP, Bickel U, Barz H, Gusztony G, et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991;29:487-92.
61. Enz A, Chappuis A, Probst A. Different influence of inhibitors of acetylcholinesterase molecular forms G1 and G4 isolated from Alzheimer's disease and control brains. In: Shafferman A, Velan E, eds. Multidisciplinary approaches to cholinesterase functions. New York: Plenum Press, 1992:243-9.
62. Forsyth DR, Wilcock GK, Morgan RA, Truman CA, Ford JM, Roberts CJ. Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease. Clin Pharmacol Ther 1989;46:634-41.
63. Cutler NR, Sedman AJ, Prior P, Underwood BA, Sien A, Balogh L. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease. Psychopharmacol Bull 1990;26:231-4.
64. Ahlin A, Adem A, Junthe T, Ohman G, Nyback H. Pharmacokinetics of tetrahydroaminoacridine: relations to clinical and biochemical effects in Alzheimer's patients. Int Clin Psychopharmacol 1992;7:29-36.
65. Davis KL, Thai LJ, Gamzu E, Davis CS, Woolson RF, Gracon SI, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. New Engl J Med 1992;327:1253-9.
66. Gracon SI. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies. Acta Neurol Scand Suppl 1996;165:114-22.
67. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:3523-9.
68. Physicians' desk reference. 52nd ed. Montvale, NJ: Medical Economics Co., 1998:2082.
69. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
70. Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998;32:70-7.
71. Bryson HM, Benfield P. Donepezil. Drugs Aging 1997;10:234-9.
72. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors. J Med Chem 1995;38:4821-9.
73. Villalobos A, Blake JF, Biggers CK, Butler TW, Chapin DS, Chen YL, et al. Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase. J Med Chem 1994;37:2721-34.
74. Sugimoto H, Tsuchiya Y, Sugumi H, Higurashi K, Karibe N, Iimura Y, et al. Synthesis and structure relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[2-(N-benzoyl-N-phenylamino)ethyl]piperidine and related derivatives. J Med Chem 1992;35:4542-8.
75. Vidaluc J-L, Calmel F, Bigg DCH, Carilla E, Briley M. Flexible 1-[(2-amino-ethoxy)alkyl]-3-ar(o)yl(thio)ureas as novel acetylcholinesterase inhibitors. Synthesis and biochemical evaluation. J Med Chem 1995;38: 2969-73.
76. Yamanishi Y, Ogura H, Kososa T, Uchikoshi K, Sawa Y, Yamatsu K. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase in aged rats (abstract). Eur J Pharmacol 1990;183:1935.
77. Sherman KA, Messamore E. Blood cholinesterase inhibition as a guide to the efficacy of putative therapies for Alzheimer's dementia. Comparison of tacrine and physostigmine. In: Giacobini E, Becker R, eds. Current research in Alzheimer therapy. New York: Taylor and Francis, 1988:73-86.
78. Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, Yamasaki K, et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharm Ther Toxicol 1993;31:223-9.
79. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998;46(suppl 1):1-6.
80. Rogers SL, Perdomo C, Friedhoff LT. Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020 (abstract). Eur Neuropsychopharmacol 1995;5:386.
81. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15 week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021-31.
82. Friedhoff LT, Farlow MR, Mohs RC, Rogers SL. Donepezil (E2020) demonstrates significant improvements in cognitive and global function in patients in mild-to-moderately severe Alzheimer's disease (abstract). Presented at the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8-13, 1996:279.
83. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-45.
84. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998;8:67-75.
85. Thal LJ, Masur DM, Blau AD, Fuld PA, Klauber MR. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. J Am Geriatr Soc 1989;37:42-8.
86. Knapp S, Wardlow ML, Albert K, Waters D, Thal LJ. Correlation between plasma physostigmine concentration and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects. Drug Metab Dispos 1990;19:400-4.
87. Atack JR, Yu QS, Soncrant TT, Brossi A, Rapoport SI. Comparative inhibitory effects of various physostigmine analogs against acetyl- and butyrylcholinesterases. J Pharmacol Exp Ther 1989;249:194-202.
88. Hartvig P, Wilklund L, Lindstrom B. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anaesthesiol Scand 1986;30:177-82.
89. Thal LJ, Masur DM, Sharpless NS, Fuld PA, Davies P. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:627-36.
90. Sharpless NS, Thal LJ. Plasma physostigmine concentrations after oral administration. Lancet 1985;1:1397-8.
91. Becker R, Giacobini E. Advances in the therapy of Alzheimer's disease. Issues in the study and development of cholinomimetic therapies. In: Giacobini E, Becker R, eds. Current research in Alzheimer therapy: cholinesterase inhibitors. New York: Taylor and Francis, 1988:1-11.
92. Asthana S, Greig NH, Hedegus L, Holloway HH, Raffaele KC, Schapiro MB, et al. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 1995;58:299-309.
93. Stern Y, Sano M, Mayeaux R. Effect of oral physostigmine in Alzheimer's disease. Ann Neurol 1987;220:306-10.
94. Weinstock M, Razin M, Chorev M, Enz A. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm Suppl 1994;43:219-25.
95. Weinstock M, Razin M, Ringel I, Tashma Z, Chorev M. Acetylcholinesterase inhibition by novel carbamates: a kinetic and nuclear magnetic resonance study. In: Shafferman A, Velan E, eds. Multidisciplinary approaches to cholinesterase functions. New York: Plenum Press, 1992: 251-9.
96. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993;98:431-8.
97. Enz A, Boddeke H, Gray J, Spiegel R. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann N Y Acad Sci 1991;640:272-5.
98. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopnarmacol 1998;1:55-65.
99. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1(suppl 1):S26-34.
100. Sramek JJ, Anand R, Wardle TS, Irwin P, Hartman RD, Cutler NR. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 1996;58:1201-7.
101. Cutler NR, Sramek JJ. Tolerability profiles of AChEIs: a critical component of care for Alzheimer's patients. Int J Geriatr Psychopharmacol 1998;1(suppl):S20-5.
102. Data on file. Novartis Pharmaceutical Corp., East Hanover, NJ.
103. Cutler NR, Anand R, Hartman RD, Messina JC, Jhee SS. Antiemetic therapy for Alzheimer's patients receiving the cholinesterase inhibitor SDZ ENA 713 (abstract). Clin Pharmacol Ther 1998;63:188.
104. Lamb HM, Faulds D. Metrifonate. Drugs Aging 1997;11:490-6.
105. Reiner E, Krauthacker B, Simeon V, Skrinjaric-Spoljar M. Mechanism of inhibition in vitro of mammalian acetylcholinesterase and cholinesterase in solutions of 0,0-dimethyl 2,2,2-trichloro-1-hydroxyethyl phosphonate (Trichlorphon). Biochem Pharmacol 1975;24:717-22.
106. Nordgren I, Bergstrom M, Holmsted B, Sandoz M. Transformation and action of metrifonate. Arch Toxicol 1978;41:31-41.
107. Pacheco G, Palacios-Esquival R, Moss DE. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther 1995;274:767-70.
108. Unni LK, Womack C, Hannant ME, Becker RE. Pharmacokinetics and pharmacodynamics of metrifonate in humans. Methods Find Exp Clin Pharmacol 1994;16:285-9.
109. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-30.
110. Becker RE, Giacobini E. Mechanisms of cholinesterase inhibition in senile dementia of Alzheimer type: clinical, pharmacological and therapeutic aspects. Drug Dev Res 1988;12:163-95.
111. Snellen WM. Therapeutic properties of metrifonate. Acta Pharmacol Toxicol 1981;49:114-7.
112. Cutler NR, Jhee SS, Cyrus P, Bieber F, TanPiengco P, Sramek JJ, et al. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study. Life Sci 1998;62: 1433-41.
113. Knopman DS. Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better? Neurology 1998;50:1203-5.
114. Moriearty PL, Womack CL, Dick BW, Colliver JA, Robbs RS, Becker RE. Stability of peripheral hematological parameters after chronic acetylcholinesterase inhibition in man. Am J Hematol 1991;37:280-2.
115. Paskov DS. Galathamine. In: Kharkevich DA, ed. New neuromuscular blocking agents. Handbook for experimental pharmacology. Vol. 68. Berlin: Springer-Verlag, 1986:653-72.
116. Harvey AL. The pharmacology of galanthamine and its analogs. Pharmacol Ther 1995;68:113-28.
117. Fulton B, Benfield P. Galanthamine. Drugs Aging 1996;9:60-7.
118. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 1990;46:1553-8.
119. Mihailova D, Yamboliev I, Zhivkova Z, Tencheva J, Jovovich V. Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacol 1989;39:50-8.
120. Westra P, van Thiel JS, Vermeer GA, Soeterbroek AM, Scaf AHJ, Claessens HA. Pharmacokinetics of galanthamine (a long-acting anti-cholinesterase drug) in anaesthetized patients. Br J Anaesth 1986;58: 1303-7.
121. Bickel U, Thomsen T, Weber W, Fischer JP, Bachus R, Nitz M, et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 1991;50:420-8.
122. Sweeney JE, Hohmann CF, Moran TH, Coyle JT. A long-acting cholinesterase inhibitor reverses spatial memory in mice. Pharmacol Biochem Behav 1988;31:141-7.
123. Kewitz H, Berzewski H, Rainer M, Dal-Bianco P, Friedl E, Deisenhammer E, et al. Galanthamine, a selective nontoxic acetylcholinesterase inhibitor is significantly superior over placebo in the treatment of SDAT (abstract). Neuropsychopharmacology 1994;10(suppl):1305.
124. Wilcock G, Wilkinson D. Galanthamine hydrobromide: interim results of a group comparative, placebo-controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wiesniewski HM, eds. Alzheimer's disease: biology, diagnosis and therapeutics. Chichester, England: Wiley, 1997:661-4.
125. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996;277:728-38.
126. Post SG, Whitehouse PJ. Emerging antidementia drugs: a preliminary ethical view. J Am Geriatr Soc 1998;46:784-7.
127. Friedhoff L, Rogers S. Donepezil lengthens time to loss activities of daily living in patients with mild to moderate Alzheimer's disease -results of a preliminary evaluation (abstract). Neurology 1997;148: A100.
128. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996;47:167-77.
129. Wilcock GK, Harrold PL. Treatment of Alzheimer's disease: future directions. Acta Neurol Scand Suppl 1996;165:128-36.